Form 4: Evolent Health Executive Reports Stock Transactions

Evolent Health's President, Daniel Joseph McCarthy, reported transactions involving Class A Common Stock, including the acquisition of restricted stock units and the withholding of shares for tax obligations.

Summary

• Daniel Joseph McCarthy, President of Evolent Health, Inc., reported transactions on July 1, 2026, related to Class A Common Stock.
• He acquired 302,585 restricted stock units (RSUs) granted under the company's 2015 Omnibus Incentive Compensation Plan.
• These RSUs have a vesting schedule: 34% on July 1, 2027, and 33% on July 1, 2028, and July 1, 2029.
• Additionally, 4,582 shares were withheld to cover tax obligations upon the vesting of RSUs.
• Following these transactions, McCarthy beneficially owns 725,607 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting standard executive compensation practices and long-term incentive alignment rather than significant new financial performance indicators.

Positives

• Grant of restricted stock units indicates a long-term incentive for the executive, aligning their interests with the company's performance.
• The acquisition of RSUs suggests continued confidence in the company's future prospects by a key executive.
• The company's shareholders approved additional shares for the incentive plan on June 4, 2026, indicating ongoing support for executive compensation strategies.

Negatives

• Withholding of 4,582 shares for tax obligations represents a reduction in the net shares received by the executive upon vesting.

Risks

• The vesting schedule of the RSUs means that a significant portion of the awarded shares are not yet fully owned by the executive and are subject to continued employment.
• Future tax implications for the executive upon vesting of the remaining RSUs.

Future Outlook

The vesting schedule for the restricted stock units indicates a commitment to retaining executive talent and aligning their incentives with the company's long-term performance over the next several years.

Management Comments

• The grant of restricted stock units is part of the annual award cycle and approved by the Compensation Committee.
• The issuance of additional shares under the incentive plan was approved by shareholders at the Annual Meeting.

Industry Context

StockSavvy.ai notes that the use of restricted stock units (RSUs) for executive compensation is a common practice in the healthcare technology and managed care sectors, aimed at retaining key talent and aligning executive interests with shareholder value over the long term.

Corporate Governance

Stakeholder Impact

• Shareholders: The issuance of additional shares for the incentive plan dilutes existing ownership slightly, but is a standard practice for executive retention and motivation.
• Employees: The filing pertains to executive compensation, but the underlying incentive plan may also cover other employees.
• Management: Daniel Joseph McCarthy's compensation is directly impacted by the grant and vesting of RSUs.

Next Steps

• Vesting of restricted stock units on July 1, 2027, July 1, 2028, and July 1, 2029.
• Potential tax implications for Daniel Joseph McCarthy upon vesting of RSUs.

Key Dates

Keywords

Evolent Health, Form 4, SEC Filing, Stock Transaction, Restricted Stock Units, Executive Compensation, Class A Common Stock, Beneficial Ownership, Daniel Joseph McCarthy